334 related articles for article (PubMed ID: 27795365)
1. Entry of Botulinum Neurotoxin Subtypes A1 and A2 into Neurons.
Kroken AR; Blum FC; Zuverink M; Barbieri JT
Infect Immun; 2017 Jan; 85(1):. PubMed ID: 27795365
[TBL] [Abstract][Full Text] [Related]
2. The Light Chain Defines the Duration of Action of Botulinum Toxin Serotype A Subtypes.
Pellett S; Bradshaw M; Tepp WH; Pier CL; Whitemarsh RCM; Chen C; Barbieri JT; Johnson EA
mBio; 2018 Mar; 9(2):. PubMed ID: 29588398
[TBL] [Abstract][Full Text] [Related]
3. The C-terminal heavy-chain domain of botulinum neurotoxin a is not the only site that binds neurons, as the N-terminal heavy-chain domain also plays a very active role in toxin-cell binding and interactions.
Ayyar BV; Aoki KR; Atassi MZ
Infect Immun; 2015 Apr; 83(4):1465-76. PubMed ID: 25624352
[TBL] [Abstract][Full Text] [Related]
4. Translocation domain of botulinum neurotoxin A subtype 2 potently induces entry into neuronal cells.
Kohda T; Tsukamoto K; Torii Y; Kozaki S; Mukamoto M
Microbiol Immunol; 2020 Jul; 64(7):502-511. PubMed ID: 32301520
[TBL] [Abstract][Full Text] [Related]
5. High resolution crystal structures of Clostridium botulinum neurotoxin A3 and A4 binding domains.
Davies JR; Rees J; Liu SM; Acharya KR
J Struct Biol; 2018 May; 202(2):113-117. PubMed ID: 29288126
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the functional activity of botulinum neurotoxin subtype B6.
Kohda T; Nakamura K; Hosomi K; Torii Y; Kozaki S; Mukamoto M
Microbiol Immunol; 2017 Nov; 61(11):482-489. PubMed ID: 28898517
[TBL] [Abstract][Full Text] [Related]
7. Enhancing toxin-based vaccines against botulism.
Przedpelski A; Tepp WH; Zuverink M; Johnson EA; Pellet S; Barbieri JT
Vaccine; 2018 Feb; 36(6):827-832. PubMed ID: 29307477
[TBL] [Abstract][Full Text] [Related]
8. Isolation and functional characterization of the novel Clostridium botulinum neurotoxin A8 subtype.
Kull S; Schulz KM; Weisemann J; Kirchner S; Schreiber T; Bollenbach A; Dabrowski PW; Nitsche A; Kalb SR; Dorner MB; Barr JR; Rummel A; Dorner BG
PLoS One; 2015; 10(2):e0116381. PubMed ID: 25658638
[TBL] [Abstract][Full Text] [Related]
9. Structural Features of
Gregory KS; Mahadeva TB; Liu SM; Acharya KR
Toxins (Basel); 2022 May; 14(5):. PubMed ID: 35622602
[TBL] [Abstract][Full Text] [Related]
10. Novel ganglioside-mediated entry of botulinum neurotoxin serotype D into neurons.
Kroken AR; Karalewitz AP; Fu Z; Kim JJ; Barbieri JT
J Biol Chem; 2011 Jul; 286(30):26828-37. PubMed ID: 21632541
[TBL] [Abstract][Full Text] [Related]
11. Botulinum neurotoxin serotype C associates with dual ganglioside receptors to facilitate cell entry.
Karalewitz AP; Fu Z; Baldwin MR; Kim JJ; Barbieri JT
J Biol Chem; 2012 Nov; 287(48):40806-16. PubMed ID: 23027864
[TBL] [Abstract][Full Text] [Related]
12. Dynamin inhibition blocks botulinum neurotoxin type A endocytosis in neurons and delays botulism.
Harper CB; Martin S; Nguyen TH; Daniels SJ; Lavidis NA; Popoff MR; Hadzic G; Mariana A; Chau N; McCluskey A; Robinson PJ; Meunier FA
J Biol Chem; 2011 Oct; 286(41):35966-35976. PubMed ID: 21832053
[TBL] [Abstract][Full Text] [Related]
13. Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1.
Pier CL; Chen C; Tepp WH; Lin G; Janda KD; Barbieri JT; Pellett S; Johnson EA
FEBS Lett; 2011 Jan; 585(1):199-206. PubMed ID: 21126520
[TBL] [Abstract][Full Text] [Related]
14. Double receptor anchorage of botulinum neurotoxins accounts for their exquisite neurospecificity.
Rummel A
Curr Top Microbiol Immunol; 2013; 364():61-90. PubMed ID: 23239349
[TBL] [Abstract][Full Text] [Related]
15. Only the complex N559-glycan in the synaptic vesicle glycoprotein 2C mediates high affinity binding to botulinum neurotoxin serotype A1.
Mahrhold S; Bergström T; Stern D; Dorner BG; Åstot C; Rummel A
Biochem J; 2016 Sep; 473(17):2645-54. PubMed ID: 27313224
[TBL] [Abstract][Full Text] [Related]
16. Botulinum neurotoxin D-C uses synaptotagmin I and II as receptors, and human synaptotagmin II is not an effective receptor for type B, D-C and G toxins.
Peng L; Berntsson RP; Tepp WH; Pitkin RM; Johnson EA; Stenmark P; Dong M
J Cell Sci; 2012 Jul; 125(Pt 13):3233-42. PubMed ID: 22454523
[TBL] [Abstract][Full Text] [Related]
17. Crystal Structures of Botulinum Neurotoxin Subtypes A4 and A5 Cell Binding Domains in Complex with Receptor Ganglioside.
Gregory KS; Mojanaga OO; Liu SM; Acharya KR
Toxins (Basel); 2022 Feb; 14(2):. PubMed ID: 35202156
[TBL] [Abstract][Full Text] [Related]
18. Glycosylated SV2 and gangliosides as dual receptors for botulinum neurotoxin serotype F.
Fu Z; Chen C; Barbieri JT; Kim JJ; Baldwin MR
Biochemistry; 2009 Jun; 48(24):5631-41. PubMed ID: 19476346
[TBL] [Abstract][Full Text] [Related]
19. Exchanging the minimal cell binding fragments of tetanus neurotoxin in botulinum neurotoxin A and B impacts their toxicity at the neuromuscular junction and central neurons.
Höltje M; Schulze S; Strotmeier J; Mahrhold S; Richter K; Binz T; Bigalke H; Ahnert-Hilger G; Rummel A
Toxicon; 2013 Dec; 75():108-21. PubMed ID: 23817019
[TBL] [Abstract][Full Text] [Related]
20. Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors.
Peng L; Tepp WH; Johnson EA; Dong M
PLoS Pathog; 2011 Mar; 7(3):e1002008. PubMed ID: 21483489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
